A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
2022-06-28
عنوان الدراسة
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
داعم الدراسة
King Faisal Specialist Hospital and Research Centre
دواء الدراسة
DOCETAXEL Paclitaxel TAMOXIFEN Letrozole
رقم بروتوكول الدراسة
S1007
حالة الدراسة
Ongoing
موقع الدراسة
KFSH & RC-R
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。